UNSPSC 51432701: Nicaraven

This classification denotes a calcium channel blocker with the molecular formula C15H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UD8PEV6JBD, chemically known as 1,2-bis(nicotinamido)propane but generally known as nicaraven, which bears US NIH Compound Identifier 71234. European Medicines Agency schedules Nicaraven in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09224MIG.

UNSPSC 51432701 Nicaraven, a Commodity code, covers emergency pharmaceutical agents and specialty medications that state and local health and public safety agencies procure for operational use. State and local governments buying under this code are acquiring advanced life support medications, generic pharmaceuticals, and over-the-counter products for fire rescue services, health plan administration, and facility-wide distribution through established wholesale channels. The issuing bodies span city purchasing departments (like Tampa's), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances coordinating procurement across member jurisdictions and participating states. Scope includes sealed bid solicitations for specific medication line items with strict expiration and quality requirements, as well as preliminary RFI and RFP activity to establish framework agreements with manufacturers and distributors capable of direct contracting, competitive pricing models, and compliance with FDA, cGMP, and Drug Supply Chain Security Act standards.

Recent activity appears concentrated in Florida and Texas, with multistate cooperative purchasing extending reach across member states including Oregon and Minnesota. The City of Tampa's Purchasing Department issued IFB No. 26P00188 for Advanced Life Support Medications (due April 8, 2026, with an estimated contract value of $40,000) requiring supply of Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue under a one-year term with renewal options and a 5 percent SLBE bid discount. The Texas Health and Human Services Commission posted RFI No. HHS0017013 (due April 3, 2026) to gather vendor capabilities for establishing direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (due March 26, 2026) seeking manufacturers of generic and OTC products for distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and operational compliance.